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Background/aim: Midkine (MK), a heparin-binding growth factor, has an important role in cancer progression. The aim of this study
was to determine MK expression in breast tissue and the preoperative and postoperative serum levels of patients with breast cancer.
Materials and methods: Sixty-one patients with breast cancer participated in our study. The MK serum levels were measured pre- and
postoperatively for these patients. We also analyzed breast tissues of the 61 patients immunohistochemically. We examined serum
midkine levels in 49 healthy volunteers.
Results: MK expression was observed in 44 (72.1%) of 61 breast cancer patients. In breast cancer patients the serum MK levels (3.68 ±
2.13 ng/mL (mean ± SD)) were significantly higher than in the control group (1.77 ± 0.38 ng/mL) before tumor removal (P = 0.000).
After tumor removal, serum MK levels (2.47 ± 1.00 ng/mL) were significantly (P = 0.000) decreased according to preoperative levels.
Increased serum levels of MK were related with tumor stages when clinical parameters were analyzed.
Conclusion: We found that increased serum MK levels and protein expressions were associated with the carcinogenesis of breast cancer.
MK levels decreased after tumor removal. According to our findings, MK might be a useful tumor marker for patients with breast cancer.
Key words: Midkine, breast cancer, serum, immunohistochemistry, real-time quantitative PCR, ELISA

1. Introduction
Growth factors are proteins with low molecular weight
that establish intercellular communication at both short
and long distances. These proteins move in specific cells
through their specific cell surface receptors and regulate
cell differentiation, migration, survival, and proliferation
(1).
It has been reported that there is a rise in more than
one growth factor in malignant tumors and such factors
play a role in tumor development, growth, invasion,
angiogenesis, and metastasis. As one of the growth factors,
midkine (MK) has been investigated recently in studies
focusing on elucidating the process of carcinogenesis in
various cancer types (2–5). The product of the human
MK gene is a protein that is localized on the 11p11.2
chromosome; it consists of 143 amino acids, which are
rich in histidines and cysteine, and weighs approximately
13 kDa (6–8). MK has been reported to be a retinoic acid* Correspondence: hcsorkun@pau.edu.tr

sensitive gene product and a heparin-binding growth
factor in embryonic carcinoma cells (6,9). It has been
argued that MK increases mitotic activity and causes some
cells to turn malignant (10,11). It is said to be expressed
at a minimum level in normal tissues but at a high level
in many malignant and inflammatory diseases (12).
MK expression has been reported to increase often and
regularly in human cancer types and that it can serve as a
tumor marker and a molecular target for cancer treatment
(13). The serum MK level is said to increase considerably
in the early stages of many cancer types (14).
Today, cancer is one of the major factors leading to
human deaths. Lung, breast, prostate, and colorectal
cancers constitute nearly half of all cancer deaths and new
cancer cases. It is stated that there has been a decrease at
a rate of 0.4% in the incidence of cancer every year from
2001 to 2010. This decrease in cancer incidence was found
to occur in males while rates remained fixed in females.
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In fact, the incidence of breast cancer in women is said to
increase (15). With its different histological manifestations,
biological performance, clinical findings, and responses
to treatment, breast cancer is a disease with malignancy
having many pathological subtypes (16,17). Deaths due to
breast cancer generally occur due to the growth of distant
metastases that cannot be detected with the existing
treatments (18). Approximately 69% of women who are
diagnosed with advanced-stage breast cancer die within 5
years (19).
Breast cancer is seen in one of every four women.
Our aim was to explore the presence of MK expression in
cancerous breast tissues, which is thought to be a marker
capable of detecting cancer at an early stage, through
immunohistochemical and cDNA techniques and its
serum levels.
2. Materials and methods
Included in the study were 110 individuals who presented
to the General Surgery Breast Outpatient Clinic of the
Faculty of Medicine of Pamukkale University between
August 2013 and August 2014 and who volunteered. Care
was taken to ensure that the subjects did not have any other
disease (liver disorders, rheumatoid arthritis, diabetes,
hypertension, etc.). Our patient group consisted of 61
subjects who were diagnosed with breast cancer. As study
material, we used the subjects’ tissue samples that were
fixed in 10% formaldehyde solution and then embedded
in paraffin blocks. Serum samples were obtained from
blood samples that were taken before the patients
diagnosed with breast cancer were operated on and from
samples that were taken for routine examinations 15–30
days after the operation. The control group consisted of
49 female patients who underwent a breast operation for
noncancerous reasons and had nontumoral breast tissues,
and their preoperative serum samples were also obtained.
The pathology reports of the patients containing data
on their ages, menopause statuses, biopsy methods, and
presence of any other disease as well as their information
from the breast outpatient clinic were reviewed and
such reports were used to determine the subject groups
according to their tumor grades and stages.
2.1. Immunohistochemistry
Each case’s samples with maximum microvessel density and
minimum hemorrhage and necrosis were selected and were
fixed in 10% formalin, and sections of 3–5 µm from paraffinembedded tissue were placed on adhesive polylysinecoated slides. Sections were incubated in blocking solution
to eliminate nonspecific immunoreactivity and then the
anti-MK monoclonal antibody (mid green (C terminus)
rabbit monoclonal antibody, Medical Biogen) was reacted
with it. After removal of excess antibody by washing with
PBS, the samples marked with horseradish peroxidase
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goat antimouse or antirabbit antibodies were incubated
for 60 min. DAB substrate reaction can be monitored
by the system and opposite sections were treated with a
hematoxylin staining procedure (20,21). Samples were
considered negative if less than 5% of the cells stained
for MK. Weak positive was defined as 5%–25% staining,
positive as 25%–50% staining, and strongly positive as
more than 50% of cells stained positively in cytoplasm
(22).
Each section was evaluated by two pathologists without
patient identification information and clinical diagnosis
was performed under a conventional light microscope.
2.2. RNA extraction and cDNA synthesis
Total RNA from formalin-fixed, paraffin-embedded
(FFPE) sections of 4–5 µm was isolated using the
RNeasy FFPE kit (QIAGEN, Germany) according to the
manufacturer’s instructions. Total RNA concentrations
were measured with a biophotometer (Eppendorf,
Germany) and 1 µg of RNA was used as a template for
the synthesis of complementary DNA (cDNA) using the
QuantiTect Reverse Transcription Kit (QIAGEN). Reverse
transcription was carried out 42 °C for 15 min followed
by incubation at 95 °C for 3 min. The cDNAs were stored
at –20 °C until they were used as a template in real-time
PCR.
2.2.1. Real-time quantitative PCR
Quantitation of the MK gene and an internal reference gene
(β-actin) at mRNA level was done using a fluorescencebased real-time detection method (LightCycler 2.0,
Roche, Germany). Final reaction volume for the analysis
of MK expression at mRNA level was 20 µL: 2 µL of each
primer (final concentration: 0.5 µM), 2 µL of probe (final
concentration: 0.2 µM), 4 µL of 5X LightCycler TaqMan
Master Mix, 5 µL of DNA or cDNA sample, and 5 µL of
PCR-grade water. The cycling conditions were 95 °C for 10
min, followed by 45 cycles at 95 °C for 10 s, 60 °C for 20 s,
and 72 °C for 1 s. All runs included one negative DNA or
cDNA control consisting of DNase- and RNase-free water.
MK expression at mRNA level was relatively quantified
using β-actin in each tumor and the final results were
obtained with LightCycler software (version 3).
2.3. Serum MK measurement
Serums were separated by centrifuging the blood samples
for approximately 30 min after they were taken into
plain gelled tubes. The serums were then stored at –20
°C immediately after they were separated until the time
they would be studied. When the measurements were to
be carried out, the frozen serums were melted at room
temperature and 100 µL of these serums were used for
measurements. After performing the procedure steps as
instructed by the ELISA kit (Cusabio, China), readings
were taken at 450 nm to measure MK levels in ng/mL.
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2.4. Statistical analysis
Statistical analysis was performed with SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables were
expressed as mean ± standard deviation and categorical
variables as numbers and percentages. Continuous
variables were compared with the independent sample
t-test or Mann–Whitney U test with one-way ANOVA. P
< 0.05 was considered statistically significant for all tests.

of breast tissues, the breast tissue samples of 17 patients
did not show any staining (Figure 1A); 17 showed weak
positive (Figure 1B), 11 positive (Figure 2A) and 16
strongly positive staining (Figure 2B) (Table 1). When the
MK expression in breast tissues was evaluated with respect
to immunohistochemical staining status, no significant
difference was found in terms of tumor diameter, lymph
node metastasis, stage, nuclear grade, histological grade,
lymphatic and neural invasion, or age.
When the MK expression at mRNA level was evaluated
through real-time relative quantification in 40 samples
chosen randomly, presence of expression at mRNA level
was seen in 3 subjects (7.5%). The immunohistochemical
characteristics of the breast tissues of the patients
who were found to have mRNA expression were also
positive. One patient had positive immunohistochemical
expression (25%–50%) in her breast tissue and the other
two patients had strongly positive expression (50%).

3. Results
When the mean age of the 61 subjects in the patient group,
which was 53.38 ± 13.74 years, was compared to that of
the control group, which was 44.00 ± 12.89 years, it was
statistically highly significant (P = 0.000). Two of our
subjects diagnosed with cancer were males (3.3%).
Positive MK expression was seen in the breast tissues
of 44 (72.1%) of the 61 cancer patients who took part in
our study. As for immunohistochemical staining statuses

A

B

Figure 1. MK expression in breast tissues. Breast tissue samples that did not show immunohistochemical staining (A) 40×
and that showed weak staining (B) 40×.

A

B

Figure 2. Samples that had positive (A) 100× and strongly positive (B) 40× immunohistochemical MK expression in breast
tissues.

221

ÇETİN SORKUN et al. / Turk J Med Sci
Table 1. Immunohistochemical staining statuses of breast cancer patients with respect to clinical parameters.
Clinical parameters

(0%–5%)

+
(5%–25%)

++
(25%–50%)

+++
(>50%)

Total

Tumor size (cm)

≤2
>2

5 (19.2%)
12 (34.3%)

9 (19.2%)
8 (34.3%)

4 (15.4%)
7 (20.0%)

8 (30.8%)
8 (22.9%)

26 (100%)
35 (100%)

Lymph node metastasis

+

8 (28.6%)
9 (27.3%)

7 (25%)
10 (30.3%)

5 (17.9%)
6 (18.2%)

8 (28.6%)
8 (24.2%)

28 (100%)
33 (100%)

Stage

I
II
III

9 (24.3%)
5 (25%)
3 (75%)

10 (27%)
6 (30%)
1 (25%)

8 (21.6%)
3 (15%)
0 (0%)

10 (27%)
6 (30%)
0 (0%)

37 (100%)
20 (100%)
4 (100%)

Nuclear grade

2
3

3 (20%)
14 (30.4%)

3 (20%)
14 (30.4%)

5 (33.3%)
6 (13.0%)

4 (26.7%)
12 (26.1%)

15 (100%)
46 (100%)

Histological grade

1
2
3

0 (0%)
7 (25.9%)
10 (32.3%)

2 (66.7%)
8 (29.6%)
7 (22.6%)

0 (0%)
7 (25.9%)
4 (12.9%)

1 (33.3%)
5 (18.5%)
10 (32.3%)

3 (100%)
27 (100%)
31 (100%)

Lymphatic and perineural invasion

+

9 (23.7%)
8 (34.8%)

12 (31.6%)
5 (21.7%)

9 (23.7%)
2 (8.7%)

8 (21.1%)
8 (34.8%)

38 (100%)
23 (100%)

Age

<50
≥50

9 (23.1%)
8 (36.4%)

12 (30.8%)
5 (22.7%)

7 (17.9%)
4 (18.2%)

11 (28.2%)
5 (22.7%)

39 (100%)
22 (100%)

17

17

11

16

61

Total

Staining statuses: 0%–5% negative (-), 5%–25% weak positive (+), 25%–50% positive (++), and >50% strongly positive (+++).

However, when the MK expression in breast tissues was
evaluated immunohistochemically, we could not obtain
any mRNA expression although we had other patients
who had positive and strongly positive staining.
The mean serum MK level was 1.77 ± 0.38 ng/mL
(mean ± SD) in the healthy individuals who took part in our
study and formed the control group. When the individuals
who formed the control group were assessed for their
menopausal status, no difference was seen between the
serum MK levels of the patients in menopause (1.65 ± 0.22
ng/mL) and those of the patients in premenopausal period
(1.84 ± 0.44 ng/mL) (P = 0.978).
When we compared the mean preoperative serum MK
level of the patient group (3.68 ± 2.13 ng/mL) with the
mean serum MK level of the control group (1.77 ± 0.38
ng/mL), we found that the serum MK level of the patient
group was considerably higher and it was statistically
highly significant. A comparison of the serum MK level
of the patient group before the operation (3.68 ± 2.13 ng/
mL) with that after the removal of the tumor (2.47 ± 1.00
ng/mL) showed that postoperative MK level dropped and
this was statistically highly significant (P = 0.000) (Figure
3). There was not any statistical significance when the
preoperative serum MK levels of the patients who had a
tumor diameter of 2 cm or less and of the patients who
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had a tumor diameter larger than 2 cm were compared (P
= 0.924). Again, no statistical significance was found when
the mean serum MK level of the patients who had lymph
node metastasis was compared with the mean serum MK
level of the patients who had no lymph node metastasis
(Table 2).
When we grouped our patients by cancer stages, we
had one patient at stage III and three patients at stage IV.
Since the number of patients at these two stages was small,
we considered them to be in the same group and grouped
them to be at stage III. The serum MK levels of the patients
who were at stage III before their tumors were removed
were higher than the serum MK levels of the patients at
both stage I and stage II and this was statistically significant.
The postoperative serum MK levels were close to each
other in all stages and this was not statistically significant.
As there was only one nuclear grade stage 1 patient, she
was included in stage 2, and thus nuclear grade stages 2
and 3 were assessed. When MK levels were analyzed in
terms of nuclear and histological grades, no statistical
significance was seen. When we explored the mean MK
levels of the patients who had a lymphatic invasion and/
or neural invasion, they showed an increase in those who
had a lymphatic invasion and the increase was higher in
those who had a neural invasion. The serum MK levels of
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Midkine level
ng/mL
4.00

3.68

3.50
3.00
2.47

2.50
2.00

1.77

1.50
1.00
0.50
0.00

465
466

Control

Preopera ve (pa ent)

Postopera ve (pa ent)

Figure 3. Serum MK levels of control and patients groups.

Figure 3: Serum MK levels of control and patients groups.

Table 2. Serum MK levels of breast cancer patients with respect to their clinical parameters.

Clinical parameters
467

(n)

*Preop.
(ng/mL)

P-values

**Postop.
(ng/mL)

P-values

Tumor size (cm)

≤2
>2

26
35

3.71 ± 2.16
3.65 ± 2.14

n.s.

2.64 ± 1.09
2.34 ± 0.93

n.s.

Lymph node metastasis

+

28
33

3.69 ± 2.26
3.66 ± 2.06

n.s.

2.53 ± 1.00
2.41 ± 1.02

n.s.

Stage

I
II
III

37
20
4

3.71 ± 2.09
3.09 ± 1.49
6.29 ± 3.61

I-III, P = 0.050
I-II, P = 0.520
II-III, P = 0.016

2.57 ± 1.03
2.26 ± 0.96
2.58 ± 1.10

n.s.

Nuclear grade

2
3

15
46

3.86 ± 1.84
3.62 ± 2.24

n.s.

2.37 ± 0.89
2.50 ± 1.05

n.s.

Histological grade

1
2
3

3
27
31

2.52 ± 0.39
3.77 ± 1.78
3.71 ± 2.50

n.s.

2.04 ± 0.20
2.60 ± 1.17
2.39 ± 0.88

n.s.

Lymphatic and perineural invasion

–
Lymph +
Neural +
Lymph+neur+

32
14
6
9

3.37 ± 1.98
3.68 ± 1.85
4.22 ± 2.12
4.40 ± 3.06

n.s.

2.28 ± 0.80
2.86 ± 1.32
3.02 ± 1.15
2.17 ± 0.85

n.s.

Age

<50
≥50

39
22

3.80 ± 2.31
3.46 ± 1.81

n.s.

2.48 ± 1.05
2.44 ± 0.94

n.s.

(Lymph+neur+: lymph and perineural invasion + ). n.s.: not significant (P > 0.05).
*Preop.: preoperative mean serum MK levels ± SD; **Postop.: postoperative mean serum MK levels ± SD.
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the patients who had both lymphatic and neural invasions
were the highest. The serum MK levels of the patients who
did not have any lymphatic or neural invasion were the
lowest, but when they were compared with those of the
patients who had lymphatic and neural invasions, this was
not statistically significant (Table 2).
Our patients who were diagnosed with breast cancer
had one or more of the following breast cancer types:
invasive ductal carcinoma (IDC), ductal carcinoma in situ
(DCIS), lobular carcinoma in situ (LCIS), and mucinous
carcinoma (Mca). There were 18 (29.5%) patients who had
IDC alone and 32 (52.5%) patients who had both the IDC
and DCIS types. All three types of IDC, DCIS, and LCIS
were found in 2 (3.3%) patients. IDC and DCIS together
with Mca were seen in 3 (4.9%) patients. One (1.6%)
person had Mca, 2 (3.3%) had LCIS, and 2 (3.3%) had
DCIS types of breast cancer. There was 1 (1.6%) patient
who had both IDC and Mca types.
We assessed our patients as the IDC and DCIS groups
with respect to their breast cancer types. In the IDC group,
the serum MK levels of the patients who had no lymph
node metastasis were lower than those of the patients who
had lymph node metastasis, but this was not statistically
significant. The mean serum MK level of the DCIS group
patients was higher than that of the IDC group patients
with or without lymph node metastasis. While a significant
drop was seen in the postoperative mean serum MK level
of the DCIS patients, the drop in the serum MK level of
IDC patients was less (Table 3).
4. Discussion
When expressed by tumor cells and/or stromal cells, growth
factors contribute to a large extent to tumor formation
and development. A large number of studies have shown
that the level of growth factors in circulation increases in
cancer patients compared to healthy individuals and such
growth factors may stimulate focuses of metastasis in an
endocrinal way (23). MK is a multifunctional growth
hormone that can induce various effects in the targeted

cells including nerve cells, neutrophils, macrophages,
smooth muscle cells, fibroblasts, and tumor cells. It plays a
role in tumor development, growth, invasion, angiogenesis,
and metastasis (4,5). For this reason, some researchers
have focused on investigating the MK expression as
one of the growth factors and on the relationship of this
expression with tumor types and sizes and its serum values
(13,14,20,22,24).
MK mRNA and protein expressions have been
frequently seen to rise in many human carcinomas such as
lung, breast, stomach, colorectal, urinary bladder, prostate,
glioblastoma, neuroblastoma, and Wilms tumors (25–31).
It has been reported that MK expression is higher in cancer
tissues than in normal cervical tissues and 88.1% of cancer
tissues show reaction to anti-MK antibody (22).
MK expression was seen in 78.6% of osteosarcoma
tissue samples (32), 54% of samples from patients with
gastrointestinal stromal tumors (20), 89% of samples
from patients with thyroid invasive papillary carcinoma
(33), and 76.4% of gastric cardiac adenocarcinoma
samples (34). It has also been reported that excessive MK
is secreted in cancerous breast tissues (35) and positive
MK expression is seen in 86% of IDC breast cancer cases
(21). In our study, we found MK expression in 44 (72.1%)
of the breast tissue samples of 61 breast cancer patients
through the immunohistochemical method. We observed
immunohistochemical MK expression in 42 breast tissues
(73.6%) from 58 IDC cases. The immunohistochemical
findings of our study are similar to those of previous
studies.
It has been stated that in cervical cancer cases MK
protein expression is associated with cancer stages,
histology, and tumor diameter (22), and there is no
relation between tumor diameter and MK expression in
gastrointestinal stromal tumors but it has an important
association with proliferative index (20). Qin et al. pointed
out that high MK expression in breast cancer is associated
with lymph node metastasis and TNM stages but not with
age, menopausal status, or tumor diameter (21). We found

Table 3. Pre- and postoperative mean serum MK levels and immunohistochemical staining statuses of breast cancer patients with
respect to their cancer types.
Breast cancer types

n

*Preop.
(ng/mL)

IDC lymph node metastasis -

25

3.50 ± 1.67

IDC lymph node metastasis + 33

3.66 ± 2.06

DCIS lymph node metastasis - 3

5.26 ± 5.63

*Preop.: preoperative mean serum MK levels ± SD.
**Postop.: postoperative mean serum MK levels ± SD.
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P-values

**Postop.
(ng/mL)

P-values

2.61 ± 1.04
P = 0.611

2.41 ± 1.02
1.93 ± 0.08

P = 0.617

IHC -

IHC +

7 (28%)

18 (72%)

9 (27.3%)

24 (72.7%)

1 (33.3%)

2 (66.7%)
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in our study that when MK expression was assessed in an
immunohistochemical way in the cancerous breast tissues
with respect to the patients’ clinical parameters, it did not
show any statistical significance.
We were able to find expression of MK at mRNA level
in only 3 (7.5%) of the randomly selected 40 subjects in
our study. Moon et al. found the mRNA expression of MK
at a rate of 88.1% in patients with cervical cancer (22). We
think that the reason for finding a low mRNA expression in
our study is that the sample tissues studied were obtained
from paraffin blocks. Obtaining the mRNA expression
level from fresh tissues of the patients with breast cancer
could have allowed us to reach more accurate results.
It has been reported that since MK is a secretion
protein, it can also be found in the peripheral blood of
patients who have tumors that release a lot of MK. The MK
expression in esophageal carcinoma tissue has a significant
relationship with its increase in serum level (5,36,37).
It has been stated that the plasma MK level is higher
in patients with breast cancer when compared to controls
and the MK level is significantly higher in metastatic
cancer patients than the levels in primary invasive cancer
and DCIS. However, it has been reported that there is
no significant difference with respect to tumor diameter,
nodal status, clinical stage, vascular invasion, hormone
receptor status, and HER2 status (24). It was reported
in the study of Ikematsu et al. that the serum MK level
of cancer patients was higher than that of the control
group. However, it was also reported that the increase
in the serum MK level in various cancer types was not
associated with tumor diameter or stage. They reported
that the serum MK level increased even at an early stage
(stage I) in patients with stomach cancer and lung cancer.
It was observed that after surgically removing the tumor
tissues of 5 patients with liver cancer, the serum MK
level dropped significantly in 4 patients (14). When we
compared the serum MK levels of healthy individuals
and our patients diagnosed with cancer in our study, we
found that it was statistically highly significantly different.
When we measured the postoperative serum MK levels of
our patients, we saw that they decreased considerably and
there was statistical significance. When we examined our
patients with respect to their stages, we found that the mean
serum MK level of the stage III group was significantly
higher than those of the stage I group and stage II group.
The mean serum MK levels of the patients in stages I and

II were significantly higher than the mean serum MK level
of healthy individuals. Our study is similar in this respect
to the study of Krzystek-Korpacka et al., who stated that
the MK level went up depending on the cancer stages in
patients with colorectal cancer and it was significantly
high even at an early stage. It was also reported in the same
study that the serum MK level was higher in patients with
lymph node metastasis (38). Although we also found in
our study that the serum MK level was higher in patients
with lymph node metastasis, we did not find this to be
statistically significant. The serum MK level also did not
show any significance with respect to tumor diameter, age,
histological and nuclear grade, or lymphatic and neural
invasions. The serum MK levels of the IDC patients who
had lymph node metastasis were high in our study, but this
was not statistically significant. In this respect, our study
differs from that of Tanabe et al., who stated that the serum
MK level was significantly correlated with lymph node
metastasis in endometrial carcinoma (39). Nevertheless,
the fact that the postoperative decrease in the serum MK
levels was low in our IDC patients suggests that metastasis
may have occurred in these patients.
In conclusion, it has been seen in our study and other
studies that there is an increase in MK expression in the
presence of tumors. The fact that this expression increases
at the serum level even at early stages and that there is a
decrease in the serum MK level after the tumor has been
removed shows that MK can be used as a cancer marker.
However, we found in our study that the postoperative
serum MK level dropped only a little in some of the
patients. There is a need for further studies that will
monitor patients who had serum MK levels that did not
drop and investigate whether or not such serum MK
levels that remained high were associated with metastasis.
Such studies to be carried out will provide important
contributions to the use of MK as a cancer marker.
Acknowledgments
We appreciate the Scientific and Technological Research
Council of Turkey for financial support of this study
(Project No. 113S056), Nurse Döne Dinger from the
General Surgery Breast Outpatient Clinic of the Pamukkale
University Hospitals, Technician Murat Dalkıran, and
Tuncay Dural from the Clinical Laboratories of the
Pamukkale University Hospitals.

References
1.

Hunter T. Signaling—2000 and beyond. Cell 2000; 100: 113–
127.

2.

Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An
angiogenic role for the neurokines midkine and pleiotrophin in
tumorigenesis. Cancer Res 1997; 57: 1814–1819.

225

ÇETİN SORKUN et al. / Turk J Med Sci
3.

4.

5.

6.

16.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees
CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. Molecular
portraits of human breast tumours. Nature 2000; 406: 747–752.

17.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen
H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. Gene
expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. P Natl Acad Sci USA
2001; 98: 10869–10874.

18.

Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in
neural development and cancer. Cancer Lett 2004; 204: 127–
143.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;
100: 57–70.

19.

Matsubara S, Tomomura M, Kadomatsu K, Muramatsu T.
Structure of a retinoic acid-responsive gene, MK, which is
transiently activated during the differentiation of embryonal
carcinoma cells and the mid-gestation period of mouse
embryogenesis. J Biol Chem 1990; 265: 9441–9443.

Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ.
Assessing non-cancer-related health status of US cancer
patients: other-cause survival and comorbidity prevalence. Am
J Epidemiol 2013; 178: 339–349.

20.

Kaifi JT, Fiegel HC, Rafnsdottir SL, Aridome K, Schurr PG,
Reichelt U, Wachowiak R, Kleinhans H, Yekebas EF, Mann O et
al. Midkine as a prognostic marker for gastrointestinal stromal
tumors. J Cancer Res Clin Oncol 2007; 133: 431–435.

21.

Qin LL, Huang HL, Ping JL, Xu W, Li J, Dai LC. Expression
of midkine and endoglin in breast carcinomas with different
immunohistochemical profiles. APMIS 2010; 119: 103–110.

22.

Moon HS, Park W, Sung SH, Choi EA, Chung HW, Woo BH.
Immunohistochemical and quantitative competitive PCR
analyses of midkine and pleiotrophin expression in cervical
cancer. Gynecol Oncol 2003; 88: 289–297.

23.

Kuroi K, Toi M. Circulating angiogenesis regulators in cancer
patients. Int J Biol Markers 2001; 16: 5–26.

24.

Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki
S, Taketomi M, Sakuma S, Shinohara M, Iwase H et al. Midkine
in plasma as a novel breast cancer marker. Cancer Sci 2009;
100: 1735–1739.

25.

Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A,
Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T. A
new family of heparin-binding growth/differentiation factors:
increased midkine expression in Wilms’ tumour and other
human carcinomas. Cancer Res 1993; 53: 1281–1285.

26.

Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner
PG. Midkine and pleiotrophin expression in normal and
malignant breast tissue. Cancer 1994; 74: 1584–1590.

27.

Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou
T, Muramatsu T. Increased midkine gene expression in human
gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655–661.

28.

Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H,
Cnaan A, Brodeur GM. Differential expression of pleiotrophin
and midkine in advanced neuroblastomas. Cancer Res 1995;
55: 1792–1797.

29.

O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The
angiogenic factor midkine is expressed in bladder cancer, and
overexpression correlates with a poor outcome in patients with
invasive cancers. Cancer Res 1996; 56: 2515–2518.

30.

Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita
Y, Muramatsu T, Kurino T. Increased expression of midkine
during the progression of human astrocytomas. Neurosci Lett
1997; 233: 29–32.

Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S,
Noda M, Muramatsu T, Kadomatsu K. Haptotactic migration
induced by midkine. Involvement of protein-tyrosine
phosphatase zeta. Mitogen-activated protein kinase, and
phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 15868–
15875.
Muramatsu T. Midkine and pleiotrophin: two related proteins
involved in development, survival, inflammation and
tumorigenesis. J Biochem 2002; 132: 359–371.

7.

Kaname T, Kuwano A, Murano I, Uehara K, Muramatsu T, Kajii
T. Midkine gene (MDK), a gene for prenatal differentiation and
neuroregulation, maps to band 11p11.2 by fluorescence in situ
hybridization. Genomics 1993; 17: 514–515.

8.

Murasugi A, Tohma-Aiba Y. Production of native recombinant
human midkine in the yeast, Pichia pastoris. Protein Expr
Purif 2003; 27: 244–252.

9.

Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning
and sequencing of a new gene intensely expressed in early
differentiation stages of embryonal carcinoma cells and in midgestation period of mouse embryogenesis. Biochem Biophys
Res Commun 1988; 151: 1312–1318.

10.

Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H,
Muramatsu T. Midkine induces the transformation of NIH3T3
cells. Br J Cancer 1997; 75: 354–359.

11.

Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ,
Burrow CR. Midkine induces tumor cell proliferation and
bind to a high affinity signaling receptor associated with JAK
tyrosine kinase. J Biol Chem 1998; 273: 3654–3660.

12.

Muramatsu T. Midkine, a heparin-binding cytokine with
multiple roles in development, repair and diseases. Proc Jpn
Acad Ser B Phys Biol Sci 2010; 86: 410–425.

13.

Sakamoto K, Kadomatsu K. Midkine in the pathology of
cancer, neural disease, and inflammation. Pathol Int 2012; 62:
445–455.

14.

Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano
H, Okamoto K, Oda M, Sakuma S, Aikou T et al. Serum
midkine levels are increased in patients with various types of
carcinomas. Br J Cancer 2000; 83: 701–706.

15.

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP,
Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA et al.
Annual Report to the Nation on the status of cancer, 1975-2010,
featuring prevalence of comorbidity and impact on survival
among persons with lung, colorectal, breast, or prostate cancer.
Cancer 2014; 120: 1290–1314.

226

ÇETİN SORKUN et al. / Turk J Med Sci
31.

Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura
H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical
analysis of midkine expression in human prostate carcinoma.
Oncology 1999; 57: 253–257.

32.

Sueyoshi T, Jono H, Shinriki S, Ota K, Ota T, Tasaki M,
Atsuyama E, Yakushiji T, Ueda M, Obayashi K et al. Therapeutic
approaches targeting midkine suppress tumor growth and lung
metastasis in osteosarcoma. Cancer Lett 2012; 316; 23–30.

33.

Kato M, Maeta H, Kato S, Shinozawa T, Terada T.
Immunohistochemical and in situ hybridization analyses
of midkine expression in thyroid papillary carcinoma. Mod
Pathol 2000; 13: 1060–1065.

34.

Hu XF, Yao J, Gao SG, Yang YT, Peng XQ, Feng XS. Midkine and
syndecan1 levels correlate with the progression of malignant
gastric cardiac adenocarcinoma. Mol Med Rep 2014; 10: 1409–
1415.

35.

Miyashiro I, Kaname T, Shin E, Wakasugi E, Monden T,
Takatsuka Y, Kikkawa N, Muramatsu T, Monden M, Akiyama
T. Midkine expression in human breast cancers: expression of
truncated form. Breast Cancer Res Treat 1997; 43: 1–6.

36.

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu
K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T. Increased
serum midkine concentration as a possible tumor marker in
patients with superficial esophageal cancer. Oncol Rep 2003;
10: 411–414.

37.

Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H,
Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai
T. Preoperative serum midkine concentration is a prognostic
marker for esophageal squamous cell carcinoma. Cancer Sci
2003; 94: 628–632.

38.

Krzystek-Korpacka M, Diakowska D, Neubauer K, Gamian
A. Circulating midkine in malignant and non-malignant
colorectal diseases. Cytokine 2013; 64: 158–164.

39.

Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama
A, Takano T, Niikura H, Ito K, Kadomatsu K, Hayashi S et al.
Midkine and its clinical significance in endometrial carcinoma.
Cancer Sci 2008; 99: 1125–1130.

227

